Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research, development, and marketing of drugs and diagnostics. The company offers NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products; and AlzheimAlert, a urine test that aids physicians in the diagnosis of Alzheimer's disease. Its products under development comprise NX-1207, which in phase 3 clinical trials for the treatment of benign prostatic hyperplasia, as well as in human clinical trials for the treatment of hepatocellular carcinoma and localized prostate cancer; and NXC-4720, an antibacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans. The company’s products under development also include NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. In addition, its research and development of drugs at treatments for Alzheimer's disease and other indications; drugs for the treatment of Alzheimer’s disease that targets spherons; and neural thread protein-based drugs and oncology products. The company markets its products primarily in the United States, Canada, and Europe. It has license and collaboration agreement with Recordati Ireland Ltd for the development and commercialization of NX-1207. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in St Laurent, Canada.